Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC raised its position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 796.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 54,921 shares of the biotechnology company's stock after purchasing an additional 48,793 shares during the quarter. SG Americas Securities LLC owned 0.06% of Rocket Pharmaceuticals worth $690,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in RCKT. Wellington Management Group LLP grew its position in Rocket Pharmaceuticals by 22.8% in the 3rd quarter. Wellington Management Group LLP now owns 11,242,144 shares of the biotechnology company's stock valued at $207,642,000 after acquiring an additional 2,086,424 shares during the last quarter. Westfield Capital Management Co. LP increased its stake in Rocket Pharmaceuticals by 3.8% in the 3rd quarter. Westfield Capital Management Co. LP now owns 4,493,833 shares of the biotechnology company's stock worth $83,001,000 after buying an additional 165,911 shares during the period. Maverick Capital Ltd. lifted its holdings in Rocket Pharmaceuticals by 4.8% during the 3rd quarter. Maverick Capital Ltd. now owns 4,118,672 shares of the biotechnology company's stock valued at $76,072,000 after buying an additional 190,360 shares in the last quarter. State Street Corp boosted its position in Rocket Pharmaceuticals by 11.6% in the 3rd quarter. State Street Corp now owns 3,102,022 shares of the biotechnology company's stock valued at $57,294,000 after buying an additional 322,156 shares during the period. Finally, Geode Capital Management LLC grew its stake in Rocket Pharmaceuticals by 0.9% in the third quarter. Geode Capital Management LLC now owns 1,617,866 shares of the biotechnology company's stock worth $29,888,000 after purchasing an additional 14,256 shares in the last quarter. Institutional investors own 98.39% of the company's stock.

Rocket Pharmaceuticals Price Performance

NASDAQ:RCKT traded down $0.20 during trading hours on Monday, reaching $10.54. 871,722 shares of the company were exchanged, compared to its average volume of 1,590,605. The firm has a market cap of $961.10 million, a PE ratio of -3.83 and a beta of 0.99. The stock's 50-day moving average is $12.05 and its 200-day moving average is $16.32. The company has a current ratio of 6.05, a quick ratio of 6.05 and a debt-to-equity ratio of 0.06. Rocket Pharmaceuticals, Inc. has a twelve month low of $10.07 and a twelve month high of $31.47.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last announced its earnings results on Thursday, November 7th. The biotechnology company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.07. On average, sell-side analysts anticipate that Rocket Pharmaceuticals, Inc. will post -2.83 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on RCKT. Jefferies Financial Group began coverage on shares of Rocket Pharmaceuticals in a research note on Wednesday, December 18th. They issued a "buy" rating and a $29.00 price objective for the company. Cantor Fitzgerald reissued an "overweight" rating and set a $65.00 price target on shares of Rocket Pharmaceuticals in a research report on Tuesday, November 19th. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $39.00 price objective on shares of Rocket Pharmaceuticals in a research report on Tuesday, November 19th. Chardan Capital reissued a "buy" rating and set a $62.00 target price on shares of Rocket Pharmaceuticals in a research report on Monday, November 18th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $52.00 price target on shares of Rocket Pharmaceuticals in a research report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $47.27.

Insider Buying and Selling at Rocket Pharmaceuticals

In other news, CEO Gaurav Shah sold 11,091 shares of the business's stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $13.05, for a total transaction of $144,737.55. Following the transaction, the chief executive officer now owns 707,328 shares of the company's stock, valued at approximately $9,230,630.40. The trade was a 1.54 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last quarter, insiders sold 14,386 shares of company stock worth $185,345. Insiders own 28.50% of the company's stock.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.